Kiniksa Pharmaceuticals Ltd logo

Kiniksa Pharmaceuticals Ltd - Class A

1
NAS:KNSA (Bermuda)   Class A
$ 20.19 -1.55 (-7.13%) 04:00 PM EST
112.17
Volume:
395.19K
Avg Vol (2M):
409.77K
Volume:
395.19K
Avg Vol (2M):
409.77K

Business Description

Kiniksa Pharmaceuticals Ltd logo
Kiniksa Pharmaceuticals Ltd
NAICS : 325412 SIC : 2836
ISIN : BMG5269C1010

Share Class Description:

KNSA: Class A
Description
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.
Name Current Vs Industry Vs History
Cash-To-Debt 15.92
Equity-to-Asset -0.91
Debt-to-Equity -0.03
Debt-to-EBITDA -0.55
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 11.25
Distress
Grey
Safe
Beneish M-Score -2.9
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Book Growth Rate 11.5

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 79.19
9-Day RSI 73.46
14-Day RSI 68.86
6-1 Month Momentum % 2.53
12-1 Month Momentum % 44.87

Liquidity Ratio

Name Current Vs Industry Vs History
Days Inventory 88.63
Days Sales Outstanding 15.92
Days Payable 10.08

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8.3
Shareholder Yield % -0.12

Financials (Next Earnings Date:2024-05-02 Est.)

KNSA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:KNSA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Kiniksa Pharmaceuticals Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 270.259
EPS (TTM) ($) 0.18
Beta 0.07
Volatility % 53.74
14-Day RSI 68.86
14-Day ATR ($) 0.887808
20-Day SMA ($) 19.852
12-1 Month Momentum % 44.87
52-Week Range ($) 10.29 - 22.09
Shares Outstanding (Mil) 70.34

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Kiniksa Pharmaceuticals Ltd Filings

Filing Date Document Date Form
No Filing Data

Kiniksa Pharmaceuticals Ltd Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Kiniksa Pharmaceuticals Ltd Frequently Asked Questions

What is Kiniksa Pharmaceuticals Ltd(KNSA)'s stock price today?
The current price of KNSA is $20.19. The 52 week high of KNSA is $22.09 and 52 week low is $10.29.
When is next earnings date of Kiniksa Pharmaceuticals Ltd(KNSA)?
The next earnings date of Kiniksa Pharmaceuticals Ltd(KNSA) is 2024-05-02 Est..
Does Kiniksa Pharmaceuticals Ltd(KNSA) pay dividends? If so, how much?
Kiniksa Pharmaceuticals Ltd(KNSA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1